Clinical trial NCT00528021: A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation
Official title: A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pediculus Humanus Capitis
Head Lice
Keywords: Head Lice
Lice Infestation
Pediculosis
Pediculosis Capitis
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2007-09-11
Enrollment: 230
Sex: ALL
Minimum age (years): 2
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.

Detailed description: The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.

Eligibility criteria: Inclusion Criteria:

1. The subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent.
2. Male or female subjects who are between the ages of 2 years (24 months) and 70 years old when consent is signed.
3. Infestation with head lice as demonstrated by the presence of live lice prior to first treatment.
4. Willing and able to attend all study visits as scheduled.
5. Females of childbearing potential must have a negative urine pregnancy test at screening and before receiving a second treatment, if necessary.

Exclusion Criteria:

1. Subject and/or legal guardian has not signed informed consent.
2. Subject was treated for pediculosis within 2 weeks prior to the screening evaluation.
3. Subject with an infestation of body lice or pubic lice.
4. Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment, which in the opinion of the investigator and visiting physician could influence the results of the study.
5. Subject with other diagnoses which, in the opinion of the investigator, would interfere with efficacy or safety assessments or would preclude study participation.
6. Subject with very short (shaved) hair.
7. Subject who will not be available for follow up visits.
8. Subject has been treated with a systemic antibiotic within the previous two weeks before screening.
9. Subject has been previously enrolled in any clinical study within the past 30 days; subject may not participate in another study while participating in this study.
10. Subject with history of allergy/sensitivity to active ingredient or related products; or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.
11. Pregnant and/or nursing females.

Primary outcomes:
measure: Clinical Cure
timeFrame: Day 15 or 22
Secondary outcomes:
Other outcomes:
Locations:
city: Florida City
country: United States
facility: Global Health Associates of Miami Inc
state: Florida
Study officials:
References: